# FRESH SESSION HANDOFF -- Overnight Autonomous Run Morning Packet (2026-07-13b)

Autonomous multi-hour run continuing the mo-nextrun / Top-50 mandate. Primary resume anchor for the
morning. Read this first. Working posture: Opus orchestration + Sonnet subagents + AGY (tests);
prep-only for every catalog/Supabase/production write; all merges except #620 left for the owner.

## Baseline
- `origin/main` = df7db68 (PR #620 merged, authorized). All overnight work branched off it.
- Worktree: `C:/Projects/SSTAC-Dashboard-worktrees/top50-2026-07-13`. Primary checkout still STALE
  (deede52) + dirty -- untouched by design.
- Run artifacts: `.tmp/overnight-2026-07-13/` (RUN_STATE.md, PR_MANIFEST.md, HEARTBEAT.log,
  COMMAND_LOG.md, RESUME_PROMPT.md).

## What shipped (open PRs -- all left for OWNER MERGE; #620-only merge was authorized)
| PR | Content | Gates | State |
|----|---------|-------|-------|
| #620 | T32-applied docs source of truth | 13 green | MERGED (authorized) |
| #621 | Top-50 priority tasks deliverable (the mandate) | ALL 13 CI checks GREEN | OPEN -> ready to merge |
| #622 | Overnight decision-support pack (3 docs) + coverage tests (2 files) | local: lint PASS, docs:gate PASS, vitest 12/12 PASS; CI running at handoff | OPEN |

Review posture: per the owner's overnight instruction (do not pause for /codex-review loops), the
per-commit codex loop was ABBREVIATED for the docs + additive-tests PRs (each finding came from an
independent Sonnet subagent; tests independently verified 12/12). Full codex is RESERVED for the D1
production write. No production/catalog/Supabase write was executed.

## HITL BATCH -- owner decisions for the morning (nothing was applied)
1. **Merge PR #621** (Top-50 deliverable) -- fully green.
2. **Merge PR #622** (decision-support + coverage) -- confirm CI green first.
3. **D1 dioxin-TEQ --apply** -- VALUE INDEPENDENTLY CONFIRMED: dioxin_like_teq oral TDI = 2.3e-9 mg
   TEQ/kg-bw/day at Health Canada TRV v4.0 (2025) PDF **page 42** (file
   `G:\My Drive\SABCS - Sediment Project\References\HC 2025 - Toxicological Reference Values TRV.pdf`),
   matches the catalog record exactly. Dry-run clean (1 row; source no-op). ON YOUR ATTESTATION: run
   `node scripts/matrix-options/promote-hc-dioxin-teq.mjs --reviewer "J. Nelson" --date <date> --apply`
   + add `pv-hc-dioxin-like-teq-hh-direct-oral-tdi` to `sanctionedPromotionIds` in
   `src/lib/matrix-options/provenance/__tests__/catalog.test.ts` (SAME commit) + full codex + ship.
4. **Security fixes (both gaps REAL, HIGH confidence)** -- see PR #622 doc
   `MATRIX_OPTIONS_SECURITY_RBAC_REVERIFY_2026_07_13.md`:
   - `/api/hitl-packets/*` has no role gate + is filesystem-backed (no RLS net) -> decide which role
     gates it (no "reviewer" role exists today; only admin/matrix_admin).
   - `/api/graphs/prioritization-matrix` leaks `user_id.substring(0,8)` into a survey-results tooltip
     for any logged-in user (by-design per the 07-11 comment) -> decide drop vs pseudonymize (affects
     the scatter-plot UX).
5. **Catalog easy wins surfaced by the 07-01 re-triage** (PR #622 doc `..._HITL_0701_RETRIAGE_...`):
   only 11 of ~110 items still open; lowest-friction = benzo_a_pyrene oral RfD (concordant 0.0003,
   just never wired). PHC/lmw_pahs family gap next.
6. **current_default audit** (PR #622 doc `..._CURRENT_DEFAULT_NULL_RISK_AUDIT_...`): the real
   at-risk-of-null set is only 2 tuples (endosulfan alpha/beta); do NOT blanket-set current_default
   (regresses frame-sensitivity). endosulfan default pick is the only cheap fix there.

## Risks / notes
- PR #622 CI was still running at handoff -- if any gate is RED, the tests passed locally so it is
  likely a coverage/CI-only or flake; re-check and address before merge.
- ~50 git worktrees + a 9.3GB foreign engine_v2 evaluator process exist (NOT ours) -- left alone.
- No owned OS processes left running (orphan sweep at close-out).

## Recommended next action (morning)
Merge #621, then #622 (after CI green). Then attest D1 (locator confirmed) so I apply+ship it. Then
take the two security decisions (both real) and the benzo_a_pyrene RfD wiring (cheapest catalog win).

## Close-out fields
- Claude-token spend risk for next step: low (applies are small + owner-gated).
- AGY delegation opportunity: yes (D1 tripwire scaffold, benzo_a_pyrene wiring, security-fix drafts,
  future test coverage).
